&nbsp;

STQBPFAQAccordionImage4.jpg

Mar 2018

Guidelines and Advice

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

Status: In-Review
ID: 6-13

Mar 2018

Guidelines and Advice

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Status: Current
Version: 1

Jun 2018

Regimen

NIVL+IPIL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

NIVL(MNT)

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

May 2025

Guidelines and Advice

Self-Management in Cancer: Quality Standards

Status: Current
ID: N/A
Version: 1

Nov 2018

Self-Management in Cancer Toolkit

Document

ST-QBPUpdateTracker

Dec 2018

Document

newWindow-icon-LightBlue.png

Jan 2019

Document

newWindowIconLightBlue.png

Jan 2019

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)